Research programme: corticotropin releasing factor receptor antagonists - Taisho Pharmaceutical/Janssen Pharmaceutica

Drug Profile

Research programme: corticotropin releasing factor receptor antagonists - Taisho Pharmaceutical/Janssen Pharmaceutica

Alternative Names: CRA 0316; CRA 0450; CRA 1000; CRA 1001; CRA 1065; R 278995

Latest Information Update: 18 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Janssen Pharmaceutica; Taisho Pharmaceutical
  • Class Antidepressants; Anxiolytics
  • Mechanism of Action Corticotropin releasing factor receptor 1 antagonists; Corticotropin releasing factor receptor 2 antagonists; Corticotropin-releasing-hormone-Inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Anxiety disorders; Major depressive disorder

Most Recent Events

  • 08 Aug 2017 Discontinued - Preclinical for Anxiety disorders in Japan (unspecified route)
  • 08 Aug 2017 Discontinued - Preclinical for Major depressive disorder in Japan (unspecified route)
  • 21 Oct 2009 Preclinical development in Anxiety disorders is ongoing in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top